IL265981A - Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy - Google Patents
Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathyInfo
- Publication number
- IL265981A IL265981A IL265981A IL26598119A IL265981A IL 265981 A IL265981 A IL 265981A IL 265981 A IL265981 A IL 265981A IL 26598119 A IL26598119 A IL 26598119A IL 265981 A IL265981 A IL 265981A
- Authority
- IL
- Israel
- Prior art keywords
- nephropathy
- immunoglobulin
- methods
- human subject
- subject suffering
- Prior art date
Links
- 208000010159 IgA glomerulonephritis Diseases 0.000 title 1
- 201000001474 proteinuria Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Animal Husbandry (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662407979P | 2016-10-13 | 2016-10-13 | |
| US15/399,524 US10736960B2 (en) | 2016-01-05 | 2017-01-05 | Methods for inhibiting fibrosis in a subject in need thereof |
| US15/470,647 US20170253667A1 (en) | 2016-01-05 | 2017-03-27 | Methods for inhibiting fibrosis in a subject in need thereof |
| US201762527926P | 2017-06-30 | 2017-06-30 | |
| PCT/US2017/056386 WO2018071701A1 (en) | 2016-10-13 | 2017-10-12 | Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL265981A true IL265981A (en) | 2019-06-30 |
Family
ID=61906454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL265981A IL265981A (en) | 2016-10-13 | 2019-04-11 | Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP3525798A4 (en) |
| JP (1) | JP6893554B2 (en) |
| KR (1) | KR102348939B1 (en) |
| CN (2) | CN116726163A (en) |
| AU (1) | AU2017342428B2 (en) |
| BR (1) | BR112019007426A2 (en) |
| CA (2) | CA3039927C (en) |
| CL (2) | CL2019000909A1 (en) |
| GE (1) | GEP20247587B (en) |
| IL (1) | IL265981A (en) |
| JO (1) | JOP20190068A1 (en) |
| MA (1) | MA46541A (en) |
| MX (1) | MX2019004074A (en) |
| PH (1) | PH12019500711A1 (en) |
| SG (1) | SG11201902941UA (en) |
| UA (1) | UA126908C2 (en) |
| WO (1) | WO2018071701A1 (en) |
| ZA (1) | ZA201902933B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111419860A (en) * | 2020-03-19 | 2020-07-17 | 长春市儿童医院 | Glomerular lobular nephropathy modeling method |
| CN115215937B (en) * | 2021-04-15 | 2023-05-26 | 上海麦济生物技术有限公司 | Anti-human MASP-2 antibody, preparation method and application thereof |
| CN117016486B (en) * | 2023-07-20 | 2024-05-14 | 上海澎立生技医药研究有限公司 | Animal model construction method for IgA nephropathy combined membranous nephropathy |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2374819T (en) * | 2003-05-12 | 2017-07-04 | Helion Biotech Aps | Antibodies to masp-2 |
| US7919094B2 (en) * | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US8840893B2 (en) * | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US20140056873A1 (en) * | 2004-06-10 | 2014-02-27 | University Of Leicester | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation |
| US7626730B2 (en) | 2006-03-31 | 2009-12-01 | Eastman Kodak Company | Method of making a multilevel halftone screen |
| KR101788040B1 (en) * | 2009-10-16 | 2017-10-19 | 오메로스 코포레이션 | Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation |
| US9102721B2 (en) * | 2011-01-21 | 2015-08-11 | Fibrogen, Inc. | Therapeutic method |
| KR20210021101A (en) * | 2011-04-08 | 2021-02-24 | 유니버시티 오브 레스터 | Methods for treating conditions associated with masp-2 dependent complement activation |
| US9644035B2 (en) * | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| LT2704743T (en) * | 2011-05-04 | 2020-09-10 | Omeros Corporation | Compositions for inhibiting masp-2 dependent complement acitivation |
| NZ729747A (en) * | 2013-03-15 | 2020-03-27 | Omeros Corp | Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same |
| IL283373B1 (en) * | 2013-10-17 | 2024-04-01 | Omeros Corp | Masp-2 inhibitory agents containing medicaments for inhibiting masp-2-dependent complement activation and diseases related thereto |
| MY194810A (en) * | 2016-01-05 | 2022-12-16 | Omeros Corp | Methods for inhibiting fibrosis in a subject in need thereof |
| JOP20170170B1 (en) * | 2016-08-31 | 2022-09-15 | Omeros Corp | Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods |
-
2017
- 2017-06-16 JO JOP/2019/0068A patent/JOP20190068A1/en unknown
- 2017-10-12 CA CA3039927A patent/CA3039927C/en active Active
- 2017-10-12 KR KR1020197012865A patent/KR102348939B1/en active IP Right Grant
- 2017-10-12 CN CN202310450575.2A patent/CN116726163A/en active Pending
- 2017-10-12 WO PCT/US2017/056386 patent/WO2018071701A1/en unknown
- 2017-10-12 CA CA3210384A patent/CA3210384A1/en active Pending
- 2017-10-12 JP JP2019520140A patent/JP6893554B2/en active Active
- 2017-10-12 UA UAA201904866A patent/UA126908C2/en unknown
- 2017-10-12 EP EP17861108.3A patent/EP3525798A4/en active Pending
- 2017-10-12 CN CN201780060710.5A patent/CN110177557A/en active Pending
- 2017-10-12 BR BR112019007426A patent/BR112019007426A2/en active Search and Examination
- 2017-10-12 GE GEAP201715070A patent/GEP20247587B/en unknown
- 2017-10-12 MX MX2019004074A patent/MX2019004074A/en unknown
- 2017-10-12 SG SG11201902941UA patent/SG11201902941UA/en unknown
- 2017-10-12 AU AU2017342428A patent/AU2017342428B2/en active Active
- 2017-10-12 MA MA046541A patent/MA46541A/en unknown
-
2019
- 2019-04-01 PH PH12019500711A patent/PH12019500711A1/en unknown
- 2019-04-04 CL CL2019000909A patent/CL2019000909A1/en unknown
- 2019-04-11 IL IL265981A patent/IL265981A/en unknown
- 2019-05-10 ZA ZA2019/02933A patent/ZA201902933B/en unknown
- 2019-11-28 CL CL2019003485A patent/CL2019003485A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3525798A1 (en) | 2019-08-21 |
| AU2017342428B2 (en) | 2021-02-04 |
| JP6893554B2 (en) | 2021-06-23 |
| CA3039927C (en) | 2023-10-10 |
| UA126908C2 (en) | 2023-02-22 |
| CN110177557A (en) | 2019-08-27 |
| BR112019007426A2 (en) | 2019-07-02 |
| KR102348939B1 (en) | 2022-01-12 |
| CN116726163A (en) | 2023-09-12 |
| JOP20190068A1 (en) | 2019-04-01 |
| CL2019000909A1 (en) | 2019-06-14 |
| CL2019003485A1 (en) | 2020-04-13 |
| PH12019500711A1 (en) | 2019-11-18 |
| WO2018071701A1 (en) | 2018-04-19 |
| KR20190063475A (en) | 2019-06-07 |
| JP2019534271A (en) | 2019-11-28 |
| CA3210384A1 (en) | 2018-04-19 |
| CA3039927A1 (en) | 2018-04-19 |
| MX2019004074A (en) | 2019-06-10 |
| SG11201902941UA (en) | 2019-05-30 |
| ZA201902933B (en) | 2023-05-31 |
| MA46541A (en) | 2019-08-21 |
| EP3525798A4 (en) | 2020-07-08 |
| GEP20247587B (en) | 2024-01-25 |
| NZ753260A (en) | 2021-11-26 |
| AU2017342428A1 (en) | 2019-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201609238VA (en) | Binding affinity prediction system and method | |
| HUE053370T2 (en) | Method for mode switching | |
| PT3099946T (en) | Connecting means and method for connecting two parts | |
| HK1250918A1 (en) | Egfr-directed car therapy for glioblastoma | |
| ZA201702173B (en) | Sorbent for binding metal and production thereof | |
| HK1254988A1 (en) | Connecting means and method for connecting two components | |
| IL264641A (en) | Acetyl-leucine for use in treating neurodegenerative diseases | |
| PL2960001T3 (en) | Welding system and communication method for welding system | |
| HK1231556A1 (en) | Predictive method for determining tissual radiosensitivity | |
| TWI560635B (en) | System and method for rating and selecting models | |
| SG11201607485PA (en) | A method and system for enabling a payment | |
| IL260347A (en) | Therapeutic anti-cd9 antibody | |
| ZA201902933B (en) | Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy | |
| HK1244314A1 (en) | A method for predicting the risk of obesity in a subject | |
| ZA201805743B (en) | Hla-b57 open conformers | |
| GB201516617D0 (en) | Verification for payment transations | |
| IL231685A0 (en) | System and method for predictive buffering and network shaping | |
| IL231278A0 (en) | System for assistance in transition between standing and sitting and standing | |
| GB201609084D0 (en) | System for use in bioprocessing | |
| SG10201603667WA (en) | Methods and systems for making payments | |
| GB201406223D0 (en) | Method and system for facilitating a transaction | |
| HK1223431A1 (en) | Method for optimizing storage configuration for future demand and system thereof | |
| SG11201705576YA (en) | Methods for gel reduction in polyolefins | |
| PL3081725T3 (en) | Intermediate fitting for closure system | |
| HK1222029A1 (en) | Method and device for transaction control |